Deep Sequencing in Pre- and Clinical Vaccine Research - Karger Publishers

full-text ►
Deep Sequencing in Pre- and Clinical Vaccine Research - Karger Publishers

Vol. 16, No. 1-2, 2013

Issue release date: March 2013

Add to my selection Citation Download

Public Health Genomics 2013;16:62-68
(DOI:10.1159/000345611)

Fulltext PDF (113 Kb)

Paper

Deep Sequencing in Pre- and Clinical Vaccine Research Prachi P. · Donati C. · Masciopinto F. · Rappuoli R. · Bagnoli F. Novartis Vaccines, Research Center, Siena, Italy Corresponding Author

---

 Outline

• Key Words



• Abstract


• Introduction


• Genomics Is a Catalyzer for Vaccine Discovery


• Deep Sequencing for Designing Vaccines against Highly Variable Pathogens and Cancers


• Genome-Based Phylogenetic Analysis and Vaccine Coverage


• Characterization of Human Immune Response to Vaccines by RNA-seq


• Genomics to Develop Safer Vaccines


• Conclusions


• References

• Author Contacts


• Article Information


• Publication Details


• Drug Dosage / Copyright

---

  Key Words


• Deep sequencing


• Epidemiology


• Genomics


• Reverse vaccinology


• Staphylococcus aureus


• Structural biology


• Systems biology


---

  Abstract
Vaccine research has experienced a quantum leap after the beginning of the genomics era. High-throughput sequencing techniques, unlimited computing resources, as well as new bioinformatic algorithms are now changing the way we perform genomic studies. Whole genome sequencing will soon become the gold standard for phylogenetic and epidemiology studies and is already shedding new light on the dynamics of bacterial evolution. We believe that deep sequencing projects, together with structural studies on vaccine candidates, will allow targeting constant epitopes and avoid vaccine failure due to antigenic variability. Systems biology, which is expected to revolutionize vaccine research and clinical studies, greatly relies on high-throughput technologies such as RNA-seq. Furthermore, genomics is a key element to develop safer vaccines, and the accuracy of deep sequencing will allow monitoring vaccine coverage after their introduction on the market.
Copyright © 2013 S. Karger AG, Basel